Market News

Investment in a PSD-1 spray dryer will allow the company to scale-up the process to support later clinical phases and niche commercial scale.

Complements a fast growing complex product pipeline in the region.

The white paper reviews the present state of how the pharmaceutical industry maps its upstream raw material supply chain and the associated challenges that accompany it.

Company says it is committed to ensuring previous mistakes are not repeated.

The new suites are part of a £3 million investment, which has increased the company’s overall manufacturing capacity

Through this agreement, Sun Pharma commits development of Cissampelos pariera (Cipa), a botanical drug in collaboration with ICGEB.

Ritchie Mooney appointed as Sales Specialist, based in the Republic of Ireland.

Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry.

Larger Carlsbad, California facility will allow seamless scale-up customer support from clinical to commercial scales.

New event will cover full pharmaceutical value chain, bringing together key buyers and sellers of pharmaceutical ingredients, contract services, packaging, machinery/technology, finished dosage formulations and bio services within the North American ma...

4500 formulations across 60 dosage forms, with 700 APIs and 200 finished products for Western markets present at CPHI China.

Name change comes after receiving reports of name confusion in the marketplace between Brintellix and the anti-blood clotting therapy Brilinta (ticagrelor).

Biogen to focus on novel therapies for neurology.

The ruling confirms the Court's prior injunction against the manufacture or sale of the generic version of non-crush-resistant Opana ER.

Marina to pursue Phase III studies for use of intranasal ketamine in multiple indications.

Strong growth will be driven by a robust late-stage pipeline, including valuable targeted therapies such as dupilumab and ixekizumab, says GBI Research.

The proceeds will be used to further the development of GB-102, Graybug Vision’s lead drug for wet AMD, through Phase II clinical trials and to initiate a clinical program for the company’s proprietary glaucoma compound.

Flexible factory concept allows accelerated drug development and delivery to market.

Senior appointment made just weeks after the sterile manufacturing specialist unveiled a significant surge in demand for its services from the US, driven by biotechnology firms looking for small-scale aseptic manufacturing capabilities in the EU to sup...

First company to launch a generic version of Crestor to customers in the US.

200,000 sq ft state-of-the-art biopharmaceutical manufacturing facility supports expanding development pipeline and transition toward commercial stage.

New Lynx CDR connectors facilitate faster and more economic biopharma fluid management.

The system can be applied over a broad range of process conditions, including those containing temperature-sensitive active ingredients.

Combination would create complementary offerings to treat prostate cancer.

Although a number of key patent expiries will occur during the forecast period, new drugs will offset this and drive strong growth, says GBI Research.

The event will be tackling issues such as the rise of precision medicine, disruptive thinking in pharmaceutical regulation, improving patient compliance, future pharmaceutical supply chains and more.

Launching products at INTERPHEX 2016 include 1000-L bioreactor for greater flexibility and continuity for scale-up.

The commercial launch of the CAS is the first in a series of product launches that enable continuous bioprocessing.

There is a potential difference of hundreds of millions of dollars in sales at stake across therapy lines between the first-to-market product and the runner-up, says GlobalData

Also offers a powerful state-of-the-art refrigeration system with advanced temperature management.

OptiForm Solution Suite — designed to efficiently and rapidly help solve complex bioavailability challenges for early-stage molecules, using a unique toolkit of bioavailability enhancing technologies.

This new service offers a number of advantages compared with current analytical techniques.

D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles.

The rise will be small due to the government’s focus on reducing healthcare expenditure and the increasing popularity of generics, says GlobalData.

Visible particulate matter — glass — observed by the company of reserve samples.

The move comes in response to increasing demand for its products and services.

Brings more than three decades of leadership and operations experience in healthcare.

Provides manufacturing capabilities for more than 40 different product formulations.

Adds global rights to XAF5, potential first-in-class topical treatment for steatoblepharon, or undereye bags.

The expansions will help the company to meet the increasing worldwide demand for its diabetes medicines.

Facility needed to meet growing export demand for GSK respiratory medicines.

Technology aims to solve patient competence and adherence challenges, minimizing burden on health care providers and payers.

Only manufacturer to offer the antibiotic in a ready-to-use premixed presentation.

300 content sessions stimulating new ideas to propel Turkey towards a top-ten pharma economy.

Despite its strong position in the HIV space, Gilead will face significant competition from Janssen and ViiV, as potentially successful outcomes of clinical trials could shift market dynamics.

Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be sync...

Novel enzymatic, 1-step site-specific protein conjugation technology for ADC production.

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical-grade coatings.

The company signs two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.

Electronic components offer almost unlimited possibilities to display large, clear and legible counter digits required for a wide range of user age segments and medical conditions.

Acquisition enhances WuXi's structure-based drug discovery capabilities and establishes WuXi research facilities within Europe .

Help for owners of SMEs who are still unclear on how leaving or staying in the EU will affect their businesses.

Optimized performance and energy efficiency.

Companies are working together to drive product development of the Gamlen range of powder compaction analysers.

Emverm provides a new option for patients with pinworm, whipworm, roundworm and hookworm in single or mixed infections.

Webinars will discuss tablet design and tool material selection, tool features and configuration and tooling maintenance and lifecycle management.

Significantly bolsters presence in high growth developing territories and the deal firmly establishes Recipharm’s emerging market strategy.

Focus on Microbiological contamination control and risk in pharmaceuticals, cosmetics and toiletries.

Merck obtains CE mark certification for consumables of Gavi and Geri as well as for the embryo culture media suite Gems.

Kalorama thinks Pfizer will continue to spotlight its vaccine business.

New company to develop novel cell-based cancer immunotherapies in China.

Adds selective muscarinic agonists discovered and developed by Heptares to Allergan's leading CNS pipeline.

Sales in Middle East to grow significantly in next 2 years.

Agreements relate to Eisai's global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company's global epilepsy therapy, Fycompa (perampanel).

The merged company will combine deep technical expertise in process development and clinical manufacturing.

Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.

Growth due to increasing complexity around affiliates’ roles.

Global market trends, growth and forecast to 2020.

New tablet attaches to the lining of the GI tract, resists being pulled away.

The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.

In spite of similar approval numbers, the US continue to outpace Europe.

Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market.

Purchase will expand Humanwell’s and PuraCap’s US Generics platform.

The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.

ISO 8655:2002 recommends using pipettes and tips that are sourced from the same manufacturer.

Enabling direct substitution in commercial enteric pharmaceutical formulations.

Progeny 1064nm handheld Raman analyser fully compliant with EP 2.2.48 to support pharmaceutical manufacturers with rapid and reliable raw material identification.

Company receives EPA honor for 11th consecutive year.

Company recognized with ENERGY STAR Award for fifth time.

Strategic acquisition of 14 prescription brands.

BioChain to acquire exclusive development and commercial license for China.

The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.

Seventeen abstracts to be presented, including new analyses from the Phase III ARISTOTLE and AMPLIFY clinical studies and from real-world databases.

Approximately 25% of its headquarter positions to be affected.

The comprehensive range of punches and dies on display will include I Holland’s recently developed, XDF (eXtended Dwell Flat) punches.

The facility will produce APIs for a range of Novo Nordisk's current and future GLP-1 and insulin products.

Lialda patent upheld and extends through 8 June 2020.

Jury’s verdict upholds patent protections that are essential to the development of new medical treatments.

Recognized for advancing clinical research in Asia, speeding development for customers.

Survey about product launch challenges finds instances of demand forecasts off by more than 50%, leading to sales losses and reputation damage.

Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA.

Increasing prevalence of osteoporosis and growing ageing population coupled with new product launches to drive US osteoporosis drugs market through 2021.

New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data.

Placon, spun out from Blend Therapeutics, to pursue development of next generation cytotoxic oncology drugs.

Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program.

The newly allowed Patent covers Akers Bio's proprietary protein preparation which serves as the antigen and biologically active component of the tests.

Thermo Scientific Sorvall BIOS 16 centrifuge designed to provide simplified, flexible bioprocessing.

Highest product protection and maximum flexibility.

In addition to the new products, samples from I Holland’s current range of multi-tips and PharmaCote treatments and coatings will be on display.

Upon completion, the seven story building will cover a total of 8,000 m2 and include in its core a cleanroom with supportive media systems.

Penntech is a global provider of complete vial handling solutions covering washing, sterilization, filling, stoppering, capping and both tray and freeze dryer loading/unloading equipment.

Genevac compares use of a rotary evaporator and the Genevac Rocket Synergy evaporator, for the batch concentration of 2 L of winterised cannabis extract in ethanol.

Company's chairman of the board says he is confident that the company will be able to rebuild its reputation and thrive under new leadership.

ModiQuest will screen their high class in-house phage display libraries, ModiPhage.

Collaboration includes discovery programme for CAR-T cell-based oncology therapies.

The company believes it is a "first applicant" to file an ANDA for the generic version of Abraxane.

Under the new structure, Apotex will now operate along three core Lines of Business: Global Generics, Specialty Pharma and Global APIs.

The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.

The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines.

Proceedings on damages and an injunction against Sanofi and Regeneron will follow.

Companies say they plan to appeal the judgement.

Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing.

Global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.

The Postnova AF2000 MultiFlow reported to offer more flexibility, better performance and more robust results than any system before.

Proprietary Veltis technology used in FDA approved Idelvion.

Report assesses trends by chemistry type, application type, functionalities and regions to offer analytical insights about the potential demand emerging for particular pharmaceutical excipients in specific regions.